NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity - Warrants issued and outstanding (Details)

Stockholders' Equity - Warrants issued and outstanding (Details)		12 Months Ended
	Dec. 17, 2018 USD ($) shares	Sep. 30, 2019 USD ($) EquityInstruments $ / shares shares	Sep. 30, 2018	Sep. 30, 2019 $ / shares shares
Class of Stock [Line Items]
Warrants Outstanding		728,439		728,439
Warrants [Roll Forward]
Warrants, Exercised		(103,787)
Warrants, Redeemed		(76,501)
Warrants, Outstanding at the end of the period		728,439
Warrants, Exercisable as of September 30, 2019				728,439
Weighted average exercise price, Redeemed \| $ / shares		$ 55.00
Weighted average exercise price, Outstanding at the end of the period \| $ / shares		$ 20.99
Weighted average exercise price, Exercisable as of September 30, 2019 \| $ / shares				$ 20.99
Weighted average remaining contractual term, Outstanding at the beginning of the period		2 years 5 months 23 days	0 years
Weighted average remaining contractual term, Redeemed		2 years 5 months 5 days
Weighted average remaining contractual term, Outstanding at the end of the period		2 years 5 months 23 days	0 years
Weighted average remaining contractual term, Exercisable as of September 30, 2019		2 years 5 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number				6,875
Class of Warrant or Right, Right to Receive, Shares		103,787
CMU
Warrants [Roll Forward]
Assumed, Issued in connection with acquisition		103,787
Ohr
Warrants [Roll Forward]
Assumed, Issued in connection with acquisition		804,940
Weighted average exercise price, Issued in connection with license acquired \| $ / shares		$ 24.22
Weighted average remaining contractual term, Issued in connection with license acquired		2 years 8 months 1 day
Number of Warrants Recorded as Derivative Liability \| EquityInstruments		792,440
Number of Warrants Recorded as Equity \| EquityInstruments		12,500
Warrants Acquired, Redeemed in Cash \| $		$ 142,000
License Agreement with Carnegie Mellon University
Warrants [Roll Forward]
Stock Issued During Period, Shares, Purchase of Assets	835,625	820,000
Fully-diluted common stock held (in percent)	8.20%
Funding Amount \| $	$ 2,000,000
License Agreement with Carnegie Mellon University \| CMU
Class of Stock [Line Items]
Exercise Price \| $ / shares				$ 10.00
Warrants [Roll Forward]
Stock Issued During Period, Shares, Purchase of Assets		820,000
Fully-diluted common stock held (in percent)				8.20%
Funding Amount \| $		$ 2,000,000
Number of Days to Consider Qualified Sale		30 years
Class of Warrant or Right, Exercisable		101,847
December 13, 2021
Class of Stock [Line Items]
Exercise Price \| $ / shares				$ 55.00
Warrants Outstanding		20,627		20,627
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period		20,627
April 10, 2022
Class of Stock [Line Items]
Exercise Price \| $ / shares				$ 20.00
Warrants Outstanding		695,312		695,312
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period		695,312
October 31, 2019
Class of Stock [Line Items]
Exercise Price \| $ / shares				$ 20.00
Warrants Outstanding		12,500		12,500
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period		12,500